查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球硬皮病市場
市場調查報告書
商品編碼
1272773

2023-2030 年全球硬皮病市場

Global Scleroderma Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球硬皮病市場預計到 2022 年將達到 21.694 億美元，到 2030 年將達到 34.683 億美元。 預計硬皮病市場在預測期內（2023-2030 年）的複合年增長率為 6.2%。 主要市場參與者正在採取各種戰略，包括產品批准、收購、合作夥伴關係和新推出，以擴大產品範圍並加強產品組合，以進入硬皮病市場或擴大其業務範圍，以增強競爭力。

例如，2022 年 3 月 11 日，輝瑞公司收購了 Arena Pharmaceuticals，這是一家臨床階段的公司，開髮用於治療多種免疫炎症性疾病的創新潛在療法。 Arena 的管道包括兩個開發心血管資產，用於微血管閉塞的替莫格雷和繼發於系統性硬化症的雷諾現象，以及用於急性心力衰竭的 APD418。

硬皮病是一種自身免疫性結締組織和風濕性疾病，可引起皮膚和身體其他器官的炎症。 雖然是一種罕見疾病，但其侵襲性和日益流行等因素正在推動全球硬皮病市場的增長。

市場動態

研究資金和投資預計將在預測期內推動硬皮病市場的增長

硬皮病治療研究的資金和投資活動不斷增加，預計將在預測期內推動全球硬皮病市場的發展。 例如，國家硬皮病基金會能夠在 2022 年獲得研究資助，將研究經費增加一倍，達到 240 萬美元。 此外，2023 年 2 月，美國國家硬皮病基金會宣布每年撥款 160 萬美元，用於支持硬皮病新療法的鑑定和設計。

增加對抗硬皮病的舉措提供市場增長機會

為提高認識和為硬皮病患者提供支持的舉措越來越多，這為未來幾年的全球硬皮病市場帶來了有利可圖的增長機會。 例如，2023 年 1 月，為未投保的美國人提供經濟生命線的自治非營利組織 Healthwell 基金會宣布，系統性硬化症伴間質性肺病 (SSc -ILD) 擴大了一項新預算，為 ILD 患者提供經濟援助。 通過新的預算，HealthWell 打算為家庭年收入高達聯邦貧困線 500% 的患者提供高達 9,000 美元的共同支付或疾病管理保費援助。

俄烏衝突分析

俄烏衝突對市場產生了不利影響，許多研究因衝突造成的情況而被推遲，直接影響了全球硬皮病市場的增長。 例如，根據 2022 年 4 月發表的一篇新文章，俄羅斯與烏克蘭的戰爭導致醫生急於將流離失所的患者運送到未開發的治療中心，促使羅氏控股 AG 的多發性硬化症治療藥物的最新試驗受到影響。

全球經濟衰退影響分析

醫療保健行業也不能完全免受衰退的影響。 但由於其固有的性質，它比其他行業處理得更好。 然而，隨著通脹繼續上升，經濟衰退危機威脅著市場。 持續的經濟衰退導致的緊張局勢加劇可能會對未來幾年的硬皮病市場產生重大影響。

人工智能影響分析

人工智能在硬皮病診斷和治療方面的前景優勢預計將對全球硬皮病市場產生積極影響。 例如，根據美國風濕病學會 ACR Convergence 2022 年會上提出的結論，開源計算機算法 Vision Transformer (ViT) 能夠捕捉到指甲毛細血管 (NFC) 異常的照片。。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按治療方法
  • 按疾病類型
  • 最終用戶
  • 按地區

第四章市場動態

  • 影響因素
    • 主持人
      • 增加產品批准
      • 增加籌款和投資
    • 約束因素
      • 藥物的副作用
    • 機會
      • 提高認識
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏衝突分析

第八章全球經濟衰退分析

第9章人工智能的影響分析

第10章治療

  • 藥物治療
    • 免疫抑製劑
    • 磷酸二酯□ 5 抑製劑-PHA
    • 內皮素受體拮抗劑 (ERA)
    • 鈣通道阻滯劑 (CCB)
    • 前列環素類似物 (PA)
    • 止痛藥
    • 其他
  • 手術和其他治療

第 11 章按疾病類型分類

  • 系統性硬化症
    • 局限性皮膚系統性硬化症
    • 瀰漫性系統性硬化症
    • 信號硬化
  • 局部硬皮病
    • 嗎啡
    • 線狀硬皮病

第 12 章最終用戶

  • 醫院
  • 零售/在線藥店
  • 其他

第13章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第14章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十五章公司簡介

  • 輝瑞公司
    • 公司概況
    • 產品組合和說明
    • 財務摘要
    • 主要發展狀況
  • Sanofi
  • GlaxoSmithKline plc
  • Cumberland Pharmaceuticals, Inc.
  • Actelion Pharmaceuticals, Inc.（Johnson & Johnson）
  • Boehringer Ingelheim International GmbH（C.H. Boehringer Sohn Ag & Co. KG）
  • Corbus Pharmaceuticals Holdings, Inc.
  • Bayer AG
  • Gilead Sciences, Inc.
  • Allergan, Inc.（Abbvie）

第16章 附錄

簡介目錄
Product Code: PH1221

Market Overview

The global scleroderma market reached USD 2,169.4 million in 2022 and is projected to witness to reach up to USD 3,468.3 million by 2030. The scleroderma market is expected to exhibit a CAGR of 6.2% during the forecast period (2023-2030). The key market players are adopting various strategies such as product approvals, acquisitions, partnerships, and new launches to increase product reach and strengthen their product portfolios, to enter or expand their business offerings and competitiveness in the scleroderma market.

For instance, on March 11, 2022, Pfizer Inc. completed its acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases. Arena's pipeline includes two development-stage cardiovascular assets: temanogrel for microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis and APD418 for acute heart failure.

Scleroderma is an autoimmune connective tissue and rheumatic disorder that induces inflammation in the skin and other organs of the body. Though it is a rare disorder, the aggressive nature and growing prevalence among other factors are boosting the global scleroderma market growth.

Market Dynamics

The research funding and investments are expected to drive the scleroderma market growth during the forecast period

The increasing funding and investment activities for scleroderma treatment research are expected to boost the global scleroderma market over the forecast period. For instance, the National Scleroderma Foundation secured research grants in 2022, allowing double their research funding to USD 2.4 million. Additionally, in February 2023, the National Scleroderma Foundation announced its annual grant awards totaling USD 1.6 million to support identifying and designing new treatments and a cure for scleroderma.

The growing initiatives in the fight against scleroderma provide the market with growth opportunities

The increasing initiatives to spread awareness and provide support to scleroderma patients are presenting the global scleroderma market with lucrative growth opportunities in the forthcoming years. For instance, in January 2023, the HealthWell Foundation, an autonomous non-profit organization that delivers a financial lifeline for poorly insured Americans, extended a new budget to deliver financial help to individuals living with systemic sclerosis with interstitial lung disease (SSc-ILD). Via the new budget, HealthWell intends to deliver up to USD 9,000 in medication copayment or insurance premium subsidy to suitable patients with annual family earnings up to 500% of the federal poverty level for managing their disorder.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war has negatively impacted the market and because of the conflict-induced situation, many research studies have been delayed directly impacting the global scleroderma market growth. For instance, according to a new article published in April 2022, Russia's war in Ukraine has affected trials of Roche Holding AG's latest testing of multiple sclerosis medication, as physicians rush to transfer patients who have become refugees to unexplored treatment bases.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

The perspective benefits offered by AI in scleroderma diagnosis and treatment are estimated to have a positive influence on the global scleroderma market. For instance, the open-source computer algorithm Vision Transformer (ViT) could catch anomalies on nail fold capillaroscopy (NFC) pictures, according to conclusions submitted at the annual meeting of the American College of Rheumatology ACR Convergence 2022.

Segment Analysis

The global scleroderma market is segmented based on treatment, disease type, end users, and region.

The systemic sclerosis segment is estimated to hold the largest global scleroderma market share by 2030

Owing to the growing cases and new drug approvals, systemic sclerosis segment is estimated to hold a market share of around 74.6% of the entire scleroderma market by 2030. For instance, according to the University of Michigan Health, systemic sclerosis occurs in around 30 persons per million population per year and there are an estimated 125,000 active cases in the U.S. and perhaps 2.5 million worldwide. It is the most fatal of all rheumatologic diseases. Also, in April 2022, aTyr Pharma, Inc., a public biotherapeutics company obtained USFDA clearance for efzofitimod utilized in the treatment of systemic sclerosis.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global scleroderma market during the forecast period

Owing to the presence of a better action plan and its execution in this region for the scleroderma condition, the Europe region is estimated to hold about 27.6% of the global scleroderma market by 2030. For instance, over the duration of 2022, the England Rare Diseases Framework Delivery Group has persisted to assemble regularly to harmonize the delivery of England's action strategies. The group gets together publicly supported delivery members and agents of the rare condition patient and clinician communities, to observe the delivery of existing commitments, and settle on the scope of prospective action strategies.

Competitive Landscape

The major global players in the market include Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc. (Johnson&Johnson), Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc. and Allergan, Inc. (Abbvie) are among others.

Why Purchase the Report?

  • To visualize the global scleroderma market segmentation based on product, application, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of scleroderma market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global scleroderma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Approvals
      • 4.1.1.2. Increasing Fundings and Investments
    • 4.1.2. Restraints
      • 4.1.2.1. Drug Side Effects
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Awareness
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Treatment

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.1.2. Market Attractiveness Index, By Treatment
  • 10.2. Medication
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Immunosuppressors
    • 10.2.4. Phosphodiesterase 5 Inhibitors - PHA
    • 10.2.5. Endothelin Receptor Antagonists (ERA)
    • 10.2.6. Calcium Channel Blockers (CCBs)
    • 10.2.7. Prostacyclin Analogues (PA)
    • 10.2.8. Analgesics
    • 10.2.9. Others
  • 10.3. Surgery & Other Therapies

11. By Disease Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.1.2. Market Attractiveness Index, By Disease Type
  • 11.2. Systemic scleroderma*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 11.2.3. Limited Cutaneous Systemic Sclerosis Syndrome
    • 11.2.4. Diffuse Systemic Sclerosis
    • 11.2.5. Sine Sclerosis
  • 11.3. Localized scleroderma
    • 11.3.1. Morphea
    • 11.3.2. Linear Scleroderma

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail and Online Pharmacies
  • 12.4. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Pfizer, Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Sanofi
  • 15.3. GlaxoSmithKline plc
  • 15.4. Cumberland Pharmaceuticals, Inc.
  • 15.5. Actelion Pharmaceuticals, Inc. (Johnson & Johnson)
  • 15.6. Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
  • 15.7. Corbus Pharmaceuticals Holdings, Inc.
  • 15.8. Bayer AG
  • 15.9. Gilead Sciences, Inc.
  • 15.10. Allergan, Inc. (Abbvie)

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us